Format

Send to

Choose Destination
Nat Med. 2006 Jul;12(7):801-8. Epub 2006 Jun 11.

Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model.

Author information

1
Centre for Research in Neurodegenerative Diseases, 6 Queen's Park Crescent West, Toronto, Ontario M5S 3H2 Canada. j.mclaurin@utoronto.ca

Abstract

When given orally to a transgenic mouse model of Alzheimer disease, cyclohexanehexol stereoisomers inhibit aggregation of amyloid beta peptide (Abeta) into high-molecular-weight oligomers in the brain and ameliorate several Alzheimer disease-like phenotypes in these mice, including impaired cognition, altered synaptic physiology, cerebral Abeta pathology and accelerated mortality. These therapeutic effects, which occur regardless of whether the compounds are given before or well after the onset of the Alzheimer disease-like phenotype, support the idea that the accumulation of Abeta oligomers has a central role in the pathogenesis of Alzheimer disease.

PMID:
16767098
DOI:
10.1038/nm1423
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center